Protective role of toll-like receptor 4 during the initiation stage of cutaneous chemical carcinogenesis

Cancer Research

Volumn 68, Issue 2, 2008, Pages 615-622

  Yusuf, Nabiha ^a,b   Nasti, Tahseen H ^a   Long, J Alan ^a   Naseemuddin, Mohammed ^a   Lucas, Alan P ^a   Xu, Hui ^a   Elmets, Craig A ^a,b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7,12 DIMETHYLBENZ[A]ANTHRACENE; CARCINOGEN; DIMETHYLBENZ[A]ANTHRACENE; GAMMA INTERFERON; INTERLEUKIN 23; INTERLEUKIN 7; POLYCYCLIC AROMATIC HYDROCARBON; TOLL LIKE RECEPTOR 4; INTERLEUKIN 12;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER STAGING; CELL PROLIFERATION; CELLULAR IMMUNITY; CHEMICAL CARCINOGENESIS; CIRCULATION; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; LYMPHOCYTE ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN CARCINOMA; ANIMAL; C3H MOUSE; CELL PROTECTION; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; CONTACT DERMATITIS; GENETIC PREDISPOSITION; GENETICS; MOUSE MUTANT; NEOVASCULARIZATION (PATHOLOGY); PHYSIOLOGY; SECRETION; SKIN TUMOR; TUMOR CELL LINE;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; CARCINOGENS; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOPROTECTION; DERMATITIS, CONTACT; FEMALE; GENETIC PREDISPOSITION TO DISEASE; INTERLEUKIN-12; INTERLEUKIN-23; MICE; MICE, INBRED C3H; MICE, KNOCKOUT; NEOVASCULARIZATION, PATHOLOGIC; SKIN NEOPLASMS; TOLL-LIKE RECEPTOR 4;

EID: 39049104004     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-5219     Document Type: Article

References (29)

1. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006;124:783-801.
2. Akira S. TLR signaling. Curr Top Microbiol Immunol 2006;311:1-16.
3. Trinchieri G, Sher A. Cooperation of Toll-like receptor signals in innate immune defence. Nat Rev Immunol 2007;7:179-90.
4. Rifkin IR, Leadbetter EA, Busconi L, et al. Toll-like receptors, endogenous ligands, and systemic autoimmune disease. Immunol Rev 2005;204:27-42.
5. Iwasaki A, Medzhitov R. Toll like receptor control of the adaptive immune response. Nat Immunol 2004;5:987-95.
6. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-7.
7. Killeen SD, Wang JH, Andrews EJ, et al. Exploitation of the Toll-like receptor system in cancer: a double edged sword? Br J Cancer 2006;95:247-52.
8. Woods GM, Malley RC, Muller HK. The skin immune system and the challenge of tumour immunosurveillance. Eur J Dermatol 2005;15:63-9.
9. Miller LS, Modlin R. Human keratinocyte Toll-like receptors promote distinct immune responses. J Invest Dermatol 2007;127:262-3.
10. Lebre MC, Angelic MG, van der Aar L, et al. Human keratinocytes express functional Toll-like receptor 3, 4, 5, and 9. J Invest Dermatol 2007;127:331-41.
11. Mitsui H, Watanabe T, Saeki H, et al. Differential expression and function of Toll-like receptors in Langerhans cells: comparison with splenic dendritic cells. J Invest Dermatol 2004;122:95-102.
12. Matsushima H, Yamada N, Matsue H, et al. TLR3-, TLR7-, and TLR9-mediated production of proinflammatory cytokines and chemokines from murine connective tissue type skin-derived mast cells but not from bone marrow-derived mast cells. J Immunol 2004;173:531-41.
13. Kawai K, Shimura H, Minagawa M, et al. Expression of functional Toll-like receptor 2 on human epidermal keratinocytes. J Dermatol Sci 2002;30:185-94.
14. Yusuf N, Timares L, Seibert MD, et al. Acquired and innate immunity to polyaromatic hydrocarbons. Toxicol Appl Pharmacol 2007;224:308-12.
15. Klemme JC, Mukhtar H, Elmets CA. Induction of contact hypersensitivity to dimethylbenz(a)anthracene and benzo(a)pyrene in C3H/HeN mice. Cancer Res 1987;47:6074-8.
16. + IL-17-producing Tcells are important in effector functionsfor the elicitation of contact hypersensitivity responses. J Immunol 2006;177:6852-8.
17. + T cells. J Exp Med 1996;183:1001-12.
18. Inaba K, Inaba M, Romani N, et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 1992;176:1693-702.
19. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63.
20. Maeda A, Schneider SW, Kojima M, et al. Enhanced photocarcinogenesis in interleukin-12-deficient mice. Cancer Res 2006;66:2962-9.
21. Risau W. Differentiation of endothelium. FASEB J 1995;9:926-33.
22. Akira S, Sato S. Toll-like receptors and their signaling mechanisms. Scand J Infect Dis 2003;35:555-62.
23. Elmets CA, Athar M, Tubesing KA, et al. Susceptibility to the biological effects of polyaromatic hydrocarbons is influenced by genes of the major histocompatibility complex. Proc Natl Acad Sci U S A 1998;95:14915-9.
24. Numasaki M, Watanabe M, Suzuki T, et al. IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis. J Immunol 2005;175:6177-89.
25. Langowski JL, Zhang X, Wu L, et al. IL-23 promotes tumour incidence and growth. Nature 2006;442:461-5.
26. Honorati MC, Neri S, Cattini L, et al. IL-17 enhances the susceptibility of U-2 OS osteosarcoma cells to NK cell lysis. Clin Exp Immunol 2003;133:344-9.
27. Numasaki M, Fukushi J, Ono M, et al. Interleukin-17 promotes angiogenesis and tumor growth. Blood 2003;101:2620-7.
28. Benchetrit F, Ciree A, Vives V, et al. Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. Blood 2002;99:2114-21.
29. Numasaki M, Lotze MT, Sasaki H. Interleukin-17 augments tumor necrosis factor-α-induced elaboration of proangiogenic factors from fibroblasts. Immunol Lett 2004;93:39-43.